Capital Insight Partners LLC Sells 1,129 Shares of Novo Nordisk A/S (NYSE:NVO)

Capital Insight Partners LLC lowered its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 2.5% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 44,275 shares of the company’s stock after selling 1,129 shares during the quarter. Novo Nordisk A/S comprises approximately 1.2% of Capital Insight Partners LLC’s holdings, making the stock its 24th largest holding. Capital Insight Partners LLC’s holdings in Novo Nordisk A/S were worth $6,320,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Cravens & Co Advisors LLC boosted its stake in Novo Nordisk A/S by 1.0% during the first quarter. Cravens & Co Advisors LLC now owns 8,250 shares of the company’s stock worth $1,059,000 after buying an additional 85 shares in the last quarter. AA Financial Advisors LLC boosted its stake in Novo Nordisk A/S by 3.2% during the second quarter. AA Financial Advisors LLC now owns 2,805 shares of the company’s stock worth $400,000 after buying an additional 86 shares in the last quarter. Sage Rhino Capital LLC boosted its stake in Novo Nordisk A/S by 0.7% during the first quarter. Sage Rhino Capital LLC now owns 12,320 shares of the company’s stock worth $1,582,000 after buying an additional 89 shares in the last quarter. U.S. Capital Wealth Advisors LLC boosted its stake in Novo Nordisk A/S by 0.6% during the fourth quarter. U.S. Capital Wealth Advisors LLC now owns 15,421 shares of the company’s stock worth $1,595,000 after buying an additional 90 shares in the last quarter. Finally, Essex LLC boosted its stake in Novo Nordisk A/S by 2.0% during the first quarter. Essex LLC now owns 4,684 shares of the company’s stock worth $601,000 after buying an additional 90 shares in the last quarter. Institutional investors own 11.54% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the stock. StockNews.com downgraded shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Monday, August 19th. Cantor Fitzgerald reiterated an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a research note on Monday, August 19th. The Goldman Sachs Group assumed coverage on shares of Novo Nordisk A/S in a research note on Thursday, May 30th. They issued a “buy” rating and a $156.00 target price on the stock. Argus boosted their target price on shares of Novo Nordisk A/S from $125.00 to $160.00 and gave the company a “buy” rating in a research note on Monday, June 10th. Finally, BMO Capital Markets reduced their target price on shares of Novo Nordisk A/S from $170.00 to $160.00 and set an “outperform” rating on the stock in a research note on Thursday, August 8th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $145.17.

Novo Nordisk A/S Price Performance

Shares of NYSE:NVO traded up $0.09 on Friday, hitting $136.97. The stock had a trading volume of 2,112,195 shares, compared to its average volume of 4,428,083. Novo Nordisk A/S has a twelve month low of $86.96 and a twelve month high of $148.15. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.50 and a current ratio of 0.70. The firm’s 50 day moving average price is $136.22 and its 200-day moving average price is $131.47. The company has a market capitalization of $614.66 billion, a price-to-earnings ratio of 47.23, a price-to-earnings-growth ratio of 1.33 and a beta of 0.41.

Novo Nordisk A/S Cuts Dividend

The business also recently declared a semi-annual dividend, which will be paid on Monday, August 26th. Investors of record on Friday, August 16th will be given a dividend of $0.5126 per share. The ex-dividend date is Friday, August 16th. This represents a yield of 0.7%. Novo Nordisk A/S’s dividend payout ratio (DPR) is 24.83%.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.